Compare BVS & DSGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BVS | DSGN |
|---|---|---|
| Founded | 2011 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 783.2M | 853.8M |
| IPO Year | 2016 | 2021 |
| Metric | BVS | DSGN |
|---|---|---|
| Price | $14.38 | $14.99 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 4 |
| Target Price | $14.00 | ★ $15.25 |
| AVG Volume (30 Days) | ★ 810.2K | 449.9K |
| Earning Date | 05-06-2026 | 04-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 163.46 | N/A |
| EPS | ★ 0.52 | N/A |
| Revenue | ★ $568,087,000.00 | N/A |
| Revenue This Year | $7.52 | N/A |
| Revenue Next Year | $7.06 | N/A |
| P/E Ratio | $27.56 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $6.26 | $4.92 |
| 52 Week High | $15.89 | $17.25 |
| Indicator | BVS | DSGN |
|---|---|---|
| Relative Strength Index (RSI) | 61.47 | 62.41 |
| Support Level | $7.29 | $9.78 |
| Resistance Level | $15.89 | $15.86 |
| Average True Range (ATR) | 0.78 | 0.61 |
| MACD | -0.06 | 0.18 |
| Stochastic Oscillator | 51.67 | 72.90 |
Bioventus Inc is a medical device company focused on developing and commercializing products to relieve pain and address musculoskeletal conditions. The company operates through two reporting segments, U.S. and International, and its product portfolio is organized into three main business areas: Pain Treatments, Surgical Solutions, and Restorative Therapies, offering products such as hyaluronic acid injections for osteoarthritis, peripheral nerve stimulation devices, bone graft substitutes, and ultrasound-based fracture healing therapies.
Design Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the research and development of GeneTAC molecules, which are a novel class of small-molecule gene targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. Its pipeline includes Friedreich Ataxia, FECD, DM1, and Huntington's Disease. The company operates in one operating and reportable segment focused on utilizing the company's proprietary GeneTAC platform to design and develop therapeutic candidates for inherited diseases driven by nucleotide repeat expansion.